Clinical Research on Efficacy of Cassia Twig Tuckahoe Capsule and Mifepristone Combined with Laparoscopic Surgery for the Treatment of Endometriosis
article
OA: diamond
CC0
Abstract
Objective: To compare the clinical efficacy of Cassia Twig Tuckahoe capsule (Chinese Medicine) and Mifepristone combined with laparoscopic surgery for the treatment of endometriosis. Designs: Prospective cohort study. Setting: Gynecology and Obstetrics Department, Jingzhou Central Hospital, affiliated to Yangtze University. Methods: We selected 67 patients suspected with endometriosis and divided randomly into 2 groups on patient choice. Outcome Measures: Treatment efficacy, side effects, recurrence rate and pregnancy rate. Results: Comparing the effect of treatment between the two groups, the success rate was almost same (P > 0.5). However, the disappearance of pain was faster in Cassia twig Tuckahoe group (P < 0.05). One patient in mifepristone group had recurrent endometriosis after 8 months from initial treatment. Comparing the side effects between the two groups, Cassia twig Tuckahoe capsule group has fewer side effects in comparison to mifepristone group. The pregnancy rate was 72% in Cassia twig Tuckahoe group while 40% in mifepristone group. Conclusion: After analysis of the result, Cassia twig Tuckahoe capsule combined with Laparoscopy is superior to the Mifepristone combined with Laparoscopy. Cassia twig Tuckahoe capsule is a very propitious medicine for treating endometriosis for long term benefits.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (28)
- Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis via openalex
- Clinical applications of mifepristone via openalex
- Combination of CCR1 mRNA, MCP1, and CA125 Measurements in Peripheral Blood as a Diagnostic Test for Endometriosis via openalex
- Dienogest: A New Therapeutic Agent for the Treatment of Endometriosis via openalex
- Endometriosis: cost estimates and methodological perspective via openalex
- Environmental and host-associated risk factors in endometriosis and deep endometriotic nodules: A matched case–control study via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- EVIDENCE FOR THE RISK OF PELVIC ENDOMETRIOSIS BY AGE, RACE AND SOCIOECONOMIC STATUS1 via openalex
- High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis via openalex
- Immunobiology of endometriosis via openalex
- Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis via openalex
- Retrograde menstruation in healthy women and in patients with endometriosis. via openalex
- Role of transvaginal sonography in the detection of endometriomata via openalex
- The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium via openalex
- Theories on the Pathogenesis of Endometriosis via openalex
- Transferrin Receptor (CD71) Expression in Peritoneal Macrophages from Fertile and Infertile Women With and Without Endometriosis via openalex
- W4232794321 via openalex
- W1970103646 via openalex
- W2079241337 via openalex
- W2096141938 via openalex
- W2106212380 via openalex
- W2108976724 via openalex
- W2120078601 via openalex
- W2185901990 via openalex
- W2293158529 via openalex
- W2295027276 via openalex
- W3032000767 via openalex
- W68928392 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK